CSIMarket
 
Autolus Therapeutics Plc  (AUTL)
Other Ticker:  
 
 
Price: $5.8200 $0.12 2.105%
Day's High: $5.87 Week Perf: 7.58 %
Day's Low: $ 5.53 30 Day Perf: -19.72 %
Volume (M): 2,013 52 Wk High: $ 7.45
Volume (M$): $ 11,713 52 Wk Avg: $3.64
Open: $5.70 52 Wk Low: $1.61



 Market Capitalization (Millions $) 1,013
 Shares Outstanding (Millions) 174
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -195
 Cash Flow (TTM) (Millions $) -126
 Capital Exp. (TTM) (Millions $) 11

Autolus Therapeutics Plc
Autolus Therapeutics Plc is a clinical-stage biopharmaceutical company focused on developing and commercializing next-generation, programmed T-cell therapies for the treatment of cancer. They utilize their proprietary technology to engineer cell therapies with improved safety and efficacy compared to traditional approaches. Autolus is known for its innovative approach to developing personalized therapies that target and destroy cancer cells, while leaving healthy cells intact. The company's pipeline includes a range of product candidates targeting various types of blood cancers, including B-cell malignancies and multiple myeloma. Autolus Therapeutics aims to revolutionize cancer treatment by harnessing the power of the immune system to effectively and selectively eliminate cancer cells.


   Company Address: The Mediaworks London 0
   Company Phone Number: 3829 6230   Stock Exchange / Ticker: NASDAQ AUTL
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Autolus Therapeutics Achieves MHRA Certification for Nucleus Manufacturing Site Amid Challenging Revenue Scenario

Published Tue, Mar 12 2024 11:00 AM UTC

Autolus Therapeutics, a leading clinical-stage biopharmaceutical company specializing in the development of innovative immunotherapies for cancer treatment, has successfully obtained the prestigious certification from the Medicines and Healthcare products Regulatory Agency (MHRA) for its Nucleus commercial manufacturing site. This significant achievement highlights the compa...

Partnership

BioNTech and Autolus Forge Groundbreaking Partnership to Elevate CAR-T Cell Therapy in Cancer Treatment

Published Thu, Feb 8 2024 10:45 AM UTC

BioNTech and Autolus Join Forces to Propel CAR-T Cell Therapy to New Frontiers in Cancer TreatmentIn a groundbreaking move, leading biotechnology companies BioNTech and Autolus have announced a strategic collaboration aiming to revolutionize the field of CAR-T cell therapy. This partnership brings together the expertise and resources of two industry powerhouses, with the sha...

Clinical Study

Autolus Therapeutics Sparks Excitement with Groundbreaking Clinical Data Unveiled at the ASH Annual Meeting 2023

Published Sun, Dec 10 2023 1:30 AM UTC



The recently concluded American Society of Hematology (ASH) Annual Meeting for the year 2023 served as an important platform for Autolus Therapeutics to showcase their latest clinical data updates. This renowned biopharmaceutical company, specializing in the development of next-generation engineered T-cell therapies, presented groundbreaking findings that have the ...

Product Service News

Blazing a Trail in Cancer Treatment: Autolus Therapeutics' Breakthrough Therapy and Financial Challenges

Published Mon, Nov 27 2023 12:00 PM UTC

Autolus Therapeutics Submits Biologics License Application for Breakthrough Leukemia Treatment and Faces Revenue Decline: A Tale of Challenges and Opportunities
Autolus Therapeutics, a leading biopharmaceutical company specializing in the development of innovative cancer treatments, recently made headlines with its submission of a Biologics License Application (BLA) to t...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com